|
|
||||||||
1 Laboratory of Molecular Endocrinology, Division of Pediatric Endocrinology, Department of Pediatrics, Universitätsklinikum Kiel, Schwanenweg 20, D-24105 Kiel, Germany.
2 Sequenom Inc., 3595 John Hopkins Court, San Diego, CA 92121-1331.
3 Department of Clinical Chemistry, Metabolics and Molecular Genetics, University Childrens Hospital, Ludwig-Maximilians-Universität, München, Lindwurmstrasse 4, D-80337 Munich, Germany.
aAddress correspondence to this author at: Division of Pediatric Endocrinology, Department of Pediatrics, Universitätsklinikum Kiel, Schwanenweg 20, D-24105 Kiel, Germany. Fax 49-431-597-1675; e-mail sippell{at}pediatrics.uni-kiel.de.
Background: Congenital adrenal hyperplasia (CAH) is a frequent autosomal recessive disease, with a wide range of clinical manifestations, most commonly attributable to mutations in the 21-hydroxylase gene (CYP21). Large gene deletions, large gene conversions, a small 8-basepair deletion, and eight point mutations in CYP21 account for
95% of all enzyme deficiencies. We developed a new strategy for a rapid CYP21 analysis.
Methods: DNA samples from 40 CAH patients previously genotyped by direct DNA sequencing were reanalyzed by allele-specific amplification of the functional CYP21 gene followed by a multiplex minisequencing reaction using 13 primers. In addition, a second PCR that amplified a part of exon 3 was used to demonstrate the presence or absence of at least one functional gene.
Results: The assay detected the P453S mutation and nine of the most common mutations (P30L, intron 2 splice,
8bp, I172N, exon 6 cluster, V281L, F306+t, Q318X, and R356W) caused by microconversions from the CYP21P pseudogene. The concordance was 100% for detecting these mutations, including gene deletions and large gene conversions. The 40 patient DNA samples were analyzed in 1.5 working days by one technician (actual hands-on time, 3.5 h). The material cost for analyzing one sample was approximately
10.00 (US $9.00).
Conclusions: This novel mutation screening strategy rapidly detects 9095% of all mutations associated with CAH and appears applicable as a tool for confirmation of increased 17-hydroxyprogesterone found in neonatal CAH screening.
The following articles in journals at HighWire Press have cited this article:
![]() |
F. G. Riepe, O. Hiort, J. Grotzinger, W. G. Sippell, N. Krone, and P.-M. Holterhus Functional and Structural Consequences of a Novel Point Mutation in the CYP21A2 Gene Causing Congenital Adrenal Hyperplasia: Potential Relevance of Helix C for P450 Oxidoreductase-21-Hydroxylase Interaction J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2891 - 2895. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Keen-Kim, J. B. Redman, R. U. Alanes, M. M. Eachus, R. C. Wilson, M. I. New, J. M. Nakamoto, and R. G. Fenwick Validation and Clinical Application of a Locus-Specific Polymerase Chain Reaction- and Minisequencing-Based Assay for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) J. Mol. Diagn., May 1, 2005; 7(2): 236 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kosel, S. Burggraf, R. Fingerhut, H. G. Dorr, A. A. Roscher, and B. Olgemoller Rapid Second-Tier Molecular Genetic Analysis for Congenital Adrenal Hyperplasia Attributable to Steroid 21-Hydroxylase Deficiency Clin. Chem., February 1, 2005; 51(2): 298 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Krone, F. G. Riepe, J. Grotzinger, C.-J. Partsch, and W. G. Sippell Functional Characterization of Two Novel Point Mutations in the CYP21 Gene Causing Simple Virilizing Forms of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 445 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Revillion, A. Verdiere, J. Fournier, L. Hornez, and J.-P. Peyrat Multiplex Single-Nucleotide Primer Extension Analysis To Simultaneously Detect Eleven BRCA1 Mutations In Breast Cancer Families Clin. Chem., January 1, 2004; 50(1): 203 - 206. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |